Groundbreaking Study Shows Pyrimidine Nucleos(t)ide Therapy Cuts Death Risk by 95% in Rare Mitochondrial Disorder Recent findings reveal a staggering 95% decrease in mortality risk in patients with TK2 deficiency through pyrimidine nucleos(t)ide therapy, indicating a potential breakthrough in treatment.

Groundbreaking Study Shows Pyrimidine Nucleos(t)ide Therapy Cuts Death Risk by 95% in Rare Mitochondrial Disorder #None #TK2_deficiency #pyrimidine_therapy #UCB_Pharmaceuticals

Advancing Awareness and Diagnosis of Thymidine Kinase 2 Deficiency Through Genomenon and UCB Partnership Genomenon and UCB have launched a partnership to enhance awareness and diagnosis of thymidine kinase 2 deficiency, utilizing AI-driven genomic data curation for better clinical outcomes.

Advancing Awareness and Diagnosis of Thymidine Kinase 2 Deficiency Through Genomenon and UCB Partnership #USA #Ann_Arbor #UCB #Genomenon #TK2_deficiency